Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077892 | 0.79 | ALDH1A1 (0.65) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL2249604 | 0.78 | ALDH1A1 (0.65) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL16256656 | 0.75 | MAPT (0.49) | DYRK1ASMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL7239065 | 0.71 | CASR (0.49) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL11224458 | 0.71 | DYRK1A (0.55) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL11549599 | 0.71 | DYRK1A (0.54) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL22170875 | 0.70 | DYRK1A (0.50) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL92781 | 0.70 | SMN1; SMN2 (0.61) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL10761882 | 0.70 | DYRK1A (0.50) | DYRK1ASMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL1772108 | 0.69 | PDK1 (0.55) | DYRK1ASMN1; SMN2TP53MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | DYRK1A 4843/4885SMN1; SMN2 3591/4885TP53 1611/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | DYRK1A 4843/4885SMN1; SMN2 3591/4885TP53 1611/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | DYRK1A 4843/4885SMN1; SMN2 3591/4885TP53 1611/4885 |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | SERPINB1, PREP, DNPEP | DYRK1A 4802/4885SMN1; SMN2 3908/4885TP53 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.